Read more
Erythropoietin (EPO) is a chemokine hormone that is widely distributed throughout the body. In addition to its traditional role as a hormone that stimulates red blood cell production, in recent years many laboratories have shown that EPO can act as a neuroprotective compound in a variety of injury paradigms in the nervous system. Past experience with relatively safety profile of this FDA-approved drug makes it an ideal candidate to take it into clinical trials for neuroprotection. We are on the verge of major clinical trials using this drug for neuroprotection in diseases ranging from stroke, to transverse myelitis to chemotherapy-induced peripheral neuropathy. This is the first book of its kind that brings together researchers from many different disciplines of neuroscience to review the current state-of-the-art in EPO and the nervous system. This book will benefit scientists and clinicians interested in neuroprotection in the broadest sense.
List of contents
History and Biology of Erythropoietin in Hematopoietic and Non-Neural Tissues.- Expression of Erythropoietin and Its Receptor in the Central Nervous System.- Erythropoietin and Neuroprotection in the Central Nervous System: Intracellular Signaling Pathways.- Regulation of Erythropoietin Expression in the Nervous System: The Hypoxia Inducible Factor.- Erythropoietin Neuroprotection in the Term and Preterm Infant: Safety and Efficacy.- Erythropoietin for the Treatment of Acute Ischemic Stroke: Preclinical Rationale.- Erythropoietin Neuroprotection in the Retina.- Erythropoietin for Treatment of Human Brain Disease: Experience from Proof-of-Concept Trials.- Erythropoietin in Spinal Cord Injury.- Erythropoietin and Neuroprotection in the Peripheral Nervous System: In Vivo Studies.- An Endogenous Pathway Preventing Axonal Degeneration Mediated by Schwann Cell - Derived Erythropoietin.- Role of Erythropoietin in Inflammatory Pathologies of the CNS.- Development of Non-Erythropoietic Erythropoietin Variants for Neuroprotection.
Summary
Erythropoietin (EPO) is a chemokine hormone that is widely distributed throughout the body. In addition to its traditional role as a hormone that stimulates red blood cell production, in recent years many laboratories have shown that EPO can act as a neuroprotective compound in a variety of injury paradigms in the nervous system. Past experience with relatively safety profile of this FDA-approved drug makes it an ideal candidate to take it into clinical trials for neuroprotection. We are on the verge of major clinical trials using this drug for neuroprotection in diseases ranging from stroke, to transverse myelitis to chemotherapy-induced peripheral neuropathy. This is the first book of its kind that brings together researchers from many different disciplines of neuroscience to review the current state-of-the-art in EPO and the nervous system. This book will benefit scientists and clinicians interested in neuroprotection in the broadest sense.
